Traders Purchase Large Volume of SELLAS Life Sciences Group Call Options (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was the target of some unusual options trading activity on Friday. Traders purchased 79,890 call options on the stock. This represents an increase of approximately 103% compared to the average volume of 39,383 call options.

Hedge Funds Weigh In On SELLAS Life Sciences Group

Hedge funds have recently made changes to their positions in the stock. Nykredit A S acquired a new stake in SELLAS Life Sciences Group during the second quarter valued at approximately $27,000. Larson Financial Group LLC purchased a new stake in SELLAS Life Sciences Group during the fourth quarter valued at about $26,000. California State Teachers Retirement System raised its stake in SELLAS Life Sciences Group by 22.4% during the 1st quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock valued at $39,000 after purchasing an additional 1,709 shares during the period. Beacon Pointe Advisors LLC acquired a new stake in shares of SELLAS Life Sciences Group in the fourth quarter worth $38,000. Finally, Concurrent Investment Advisors LLC acquired a new position in SELLAS Life Sciences Group during the fourth quarter valued at $38,000. Institutional investors and hedge funds own 17.38% of the company’s stock.

SELLAS Life Sciences Group Trading Up 15.2%

Shares of NASDAQ SLS traded up $2.04 during midday trading on Friday, reaching $15.44. The company had a trading volume of 12,469,392 shares, compared to its average volume of 8,233,277. The stock has a market cap of $3.12 billion, a P/E ratio of -73.52 and a beta of 2.48. The business’s 50-day simple moving average is $11.69 and its 200 day simple moving average is $7.67. SELLAS Life Sciences Group has a 1 year low of $1.39 and a 1 year high of $15.88.

SELLAS Life Sciences Group (NASDAQ:SLS) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01).

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on SLS shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Friday, July 17th. Alliance Global Partners reiterated a “buy” rating on shares of SELLAS Life Sciences Group in a research note on Wednesday, August 12th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $10.00.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.